OncoMatch/Clinical Trials/NCT05045066
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
Is NCT05045066 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies non-drug interventions for localized prostate carcinoma.
This early phase I is to find out how common vitamin D insufficiency is among African American patients with a history of prostate cancer that has not spread to other parts of the body (localized) or has spread to other places in the body (metastatic) and how vitamin D insufficiency affects the immune system. This study also aims to find out if replacing vitamin D results in normalization of the immune function. Information from this study may benefit prostate cancer patients by identifying vitamin D insufficiency which in several studies had been found to contribute to more aggressive prostate cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage LOCALIZED, IV, LOCALLY RECURRENT (AJCC v8)
Localized Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Locally Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma
Prior therapy
Cannot have received: chemotherapy
Chemotherapy or surgery or radiation within the last 3 weeks prior to blood collection
Cannot have received: surgery
Chemotherapy or surgery or radiation within the last 3 weeks prior to blood collection
Cannot have received: radiation therapy
Chemotherapy or surgery or radiation within the last 3 weeks prior to blood collection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify